Loading clinical trials...
Loading clinical trials...
HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
No
Clinical Trial Site
La Mesa, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Stanford, California, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Gainesville, Georgia, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Evanston, Illinois, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Rochester, Minnesota, United States
Start Date
November 26, 2019
Primary Completion Date
May 8, 2024
Completion Date
December 2, 2026
Last Updated
January 12, 2026
655
ACTUAL participants
Vutrisiran
DRUG
Sterile Normal Saline (0.9% NaCl)
DRUG
Lead Sponsor
Alnylam Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions